Who are Glipizide GITS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: glimepiride, Glibenclamide and Metformin, Add Glimepiride, Glimepiride (HOE490), GLIMEPIRIDE + METFORMIN, Sulfonylurea (glimepiride).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glipizide-gits.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Glipizide GITS — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glipizide GITS (Glipizide GITS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea. Area: Diabetes.

phase 2 Sulfonylurea SUR1 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glipizide GITS (Glipizide GITS) — Pfizer. Sulfonylurea receptor agonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glipizide GITS TARGET	Glipizide GITS	Pfizer	phase 2	Sulfonylurea	SUR1
Comparator: glimepiride	Comparator: glimepiride	Merck Sharp & Dohme LLC	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Glibenclamide and Metformin	Glibenclamide and Metformin	Takeda	marketed	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I
Add Glimepiride	Add Glimepiride	Samsung Medical Center	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Glimepiride (HOE490)	Glimepiride (HOE490)	Sanofi	marketed	Sulfonylurea	Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Sulfonylurea (glimepiride)	Sulfonylurea (glimepiride)	GRADE Study Group	phase 3	Sulfonylurea	SUR1/ Kir6.2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea class)

Merck Sharp & Dohme LLC · 6 drugs in this class
Pfizer · 2 drugs in this class
Sanofi · 2 drugs in this class
Janssen Research & Development, LLC · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Servier Affaires Médicales · 1 drug in this class
The George Institute · 1 drug in this class
· 1 drug in this class
University of Glasgow · 1 drug in this class
GRADE Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glipizide GITS — Competitive Intelligence Brief. https://druglandscape.com/ci/glipizide-gits. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing